The BMS milestone validates the platform but is non-recurring — watch for IND filing for ATR 1072 in H2 2026 as the next real catalyst. Cash runway through proof-of-concept milestones provides ~2+ years of visibility; no near-term financing risk.
Price Chart
Executive Summary
Atrium Therapeutics reported Q1 2026 collaboration revenue of $19.6M (vs $2.0M consensus), driven by a $15M milestone from BMS, and a GAAP net loss of -$0.97/share (vs -$1.05 consensus). The company has $267.8M cash to fund operations through proof-of-concept milestones. As a recently spun-off pre-commercial biotech, the beat is mechanical (milestone-driven) and not indicative of recurring revenue — the stock will move on pipeline execution, not quarterly financials.
Key Financial Metrics
Key Facts
- Collaboration revenue of $19.6M in Q1 2026, primarily from a $15M BMS milestone payment
- GAAP net loss of -$16.6M (-$0.97/share) vs consensus -$1.05/share
- Cash and cash equivalents of $267.8M as of March 31, 2026
- IND submission for lead candidate ATR 1072 expected in H2 2026
- Up to $1.35B in R&D milestones and $825M in commercial milestones from BMS collaboration
Financial Impact
Revenue beat of $17.6M vs $2.0M consensus; EPS beat of $0.08 vs -$1.05 consensus
Risk Factors
- Pre-revenue biotech with no approved products; all value depends on clinical execution
- ATR 1072 and ATR 1086 are both in preclinical/IND-enabling stages — high clinical failure risk
- Operating expenses are ramping as a public company; G&A of $20.3M exceeded R&D of $16.7M in Q1
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-224238 |
| Document: d82207d8k.htm | 0001193125-26-224238 |
| Document: 0001193125-26-224238-index-headers.html | 0001193125-26-224238 |
| Document: 0001193125-26-224238-index.html | 0001193125-26-224238 |
| Document: 0001193125-26-224238.txt | 0001193125-26-224238 |
| 8-K Data (Synthetic) | 0001193125-26-224238 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $8.20 | awaiting T+5 | — | $8.05 (−1.83%) |
Oct 20, 2026 7d ago | Press Release | $8.00 | awaiting T+5 | — | $8.05 (+0.63%) |
Oct 9, 2026 18d ago | 8-K/A | $8.40 $7.67 | ▼ −8.69% | ▼ −6.72% | $8.05 (−4.17%) |
Oct 8, 2026 19d ago | 8-K | $8.26 $7.82 | ▲ +5.33% | ▲ +5.05% | $8.05 (+2.54%) |
Sep 21, 2026 5w ago | Press Release | $9.22 $8.42 | ▼ −8.68% | ▼ −7.49% | $8.05 (−12.69%) |
Aug 20, 2026 9w ago | Press Release | $13.20 $13.64 | ▲ +3.33% | ▲ +2.86% | $8.05 (−39.02%) |
Aug 13, 2026 10w ago | 8-K | $12.84 $13.20 | ▲ +2.80% | ▲ +4.17% | $8.05 (−37.31%) |
Aug 13, 2026 10w ago | Press Release | $12.84 $13.20 | ▲ +2.80% | ▲ +4.17% | $8.05 (−37.31%) |
Jul 20, 2026 14w ago | Press Release | $12.29 $11.57 | ▼ −5.86% | ▼ −4.63% | $8.05 (−34.50%) |
Jul 14, 2026 15w ago | 8-K | $12.30 $12.17 | ▼ −1.06% | ▼ −0.08% | $8.05 (−34.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers